The role of tamoxifen in preventing breast cancer

Cleveland Clinic Journal of Medicine

Volumn 66, Issue 1, 1999, Pages 33-40

  Overmoyer, Beth A ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RALOXIFENE; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; COMPUTER PROGRAM; DRUG EFFICACY; DRUG INDICATION; ENDOMETRIUM CANCER; EYE TOXICITY; HUMAN; LIVER CARCINOMA; PATIENT SELECTION; PERIODIC MEDICAL EXAMINATION; REVIEW; RISK MANAGEMENT; THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG APPROVAL; ENDOMETRIAL NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; PATIENT SELECTION; PIPERIDINES; PROSPECTIVE STUDIES; RALOXIFENE; RISK ASSESSMENT; TAMOXIFEN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0005812102     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.66.1.33     Document Type: Article

References (35)

1. Landis S, Murray T, Bolden S, et al. Cancer statistics, 1998. Cancer 1998; 48:6-29.
2. O'Shaughnessy J. Chemoprevention of breast cancer. JAMA 1996; 275:1349-1353.
3. Nayfield S, Karp J, Ford L, et al. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991; 83:1450-1459.
4. Love R. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J Clin Oncol 1989; 7:803-815.
5. Furr B, Jordan V. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984; 25:127-205.
6. Friedman Z. Recent advances in understanding the molecular mechanisms of tamoxifen action. Cancer Invest 1998; 16:391-396.
7. Jaiyesimi I, Buzdar A, Decker D, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13:513-529.
8. Decensi A, Fontana V, Bruno S, et al. Effect of tamoxifen on endometrial proliferation. J Clin Oncol 1996; 14:434-440.
9. Love R, Weibe D, Feyzi J, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994; 86:1534-1539.
10. Powles T, Hickish T, Kanis J, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and post-menopausal women. J Clin Oncol 1996; 14:78-84.
11. Love R, Wiebe D, Newcomb P, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115:860-864.
12. Greenwald P, Kramer B, Weed D. Expanding horizons in breast and prostate cancer prevention and early detection. J Cancer Education 1993; 8:91-107.
13. Legha S. Tamoxifen in the treatment of breast cancer. Ann Intern Med 1988; 109:219-228.
14. Tormey D, Gray R, Falkson H. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst 1996;88:1828-1833.
15. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88:1529-1542.
16. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351:1451-1467.
17. Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the Cancer Research Campaign Trail evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996; 88:1834-1839.
18. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996; 88:1543-1549.
19. Breast Cancer Trials Committee, Scottish Cancer Trials. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet 1987; 2:171-175.
20. Tormey D, Gray R, Abeloff M, et al. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an eastern cooperative oncology group trial. J Clin Oncol 1992; 10:1848-1856.
21. Ribeiro G, Swindell R. The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma-7-year results. Eur J Cancer Clin Oncol 1985; 21:897-900.
22. Nolvadex Adjuvant Trial Organization. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 1988; 57:608-611.
23. Love R, Cameron L, Connell B, et al. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991; 151:1842-1847.
24. Nayfield S, Gorin M. Tamoxifen-associated eye disease: a review. J Clin Oncol 1996; 14:1018-1026.
25. Stearns V, Gelmann E. Does tamoxifen cause cancer in humans? J Clin Oncol 1998; 16:779-792.
26. Fisher B. Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. J Clin Oncol 1996; 14:1027-1039.
27. Fisher B, Costantino J, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90:1371-1388.
28. Gail M, Brinton L, Byar D, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81:1879-1886.
29. Fisher B, Costantino J. Highlights of the NSABP breast cancer prevention trial. Cancer Control 1997; 4:78-86.
30. Smigel K. Breast cancer prevention trial under scrutiny (again) (editorial). J Natl Cancer Inst 1992; 84:1692-1694.
31. Horton J. Breast cancer care: developments in 1998. Cancer Control. 1998; 5:338-345.
32. Smith J. New computer program assesses a woman's risk for developing breast cancer. J Natl Cancer Inst 1998; 90:1332.
33. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 352:93-97.
34. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352:98-101.
35. Cummings S, Norton L, Eckert S, et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial (abstract). Proc ASCO 1998; 17:2a.